10-K/A: Immix Biopharma Files Amended 10-K to Include XBRL Tagging, Reaffirms Financial Officer Certifications

Immix Biopharma files an amendment to its 2024 annual report to include required XBRL tagging and reaffirms certifications from its principal executive and financial officers.

Summary

• Immix Biopharma, Inc. filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment was filed solely to include certain required inline XBRL tagging that was inadvertently omitted from the original filing.
• The amendment restates Part I, Item 1C (Cybersecurity) of the Original Form 10-K to include the required XBRL tagging.
• New certifications of the principal executive officer and principal financial officer are included as exhibits to the amendment.
• The amendment does not otherwise change or update any of the disclosures set forth in the Original Form 10-K and does not reflect events occurring after the filing of the Original Form 10-K.
• The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2024 was $32,432,613.
• The number of common shares outstanding as of March 11, 2025 was 27,722,108 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing addresses a compliance issue and reaffirms the accuracy of the financial statements. The discussion of cybersecurity risks is a standard disclosure.

Positives

• The company is taking steps to ensure compliance with SEC regulations by filing the amendment.
• The certifications from the CEO and CFO provide assurance regarding the accuracy of the report.

Negatives

• The original Form 10-K failed to include certain required inline XBRL tagging, necessitating the amendment.

Risks

• The company acknowledges the increasing cybersecurity risks associated with outsourcing information systems and engaging in electronic transactions.
• The company states that despite their efforts, the possibility of cybersecurity events occurring cannot be eliminated entirely.
• A potential cyberattack, security breach, industrial espionage attacks or insider threat attacks could result in financial, legal, business or reputational harm.

Future Outlook

The document does not contain specific forward-looking statements beyond the general discussion of cybersecurity risks.

Management Comments

• I, Ilya Rachman, certify that: 1. I have reviewed this Annual Report on Form 10-K/A of Immix Biopharma, Inc. (the registrant); and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
• I, Gabriel Morris, certify that: 1. I have reviewed this Annual Report on Form 10-K/A of Immix Biopharma, Inc. (the registrant); and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Industry Context

The filing highlights the increasing importance of cybersecurity in the biopharmaceutical industry, reflecting a broader trend of companies needing to invest in protecting their data and systems.

Comparison to Industry Standards

• Many companies in the biopharmaceutical industry, such as Amgen, Gilead Sciences, and Pfizer, face similar cybersecurity challenges and are required to disclose their risk management strategies in their annual reports.
• The XBRL tagging requirement is a standard practice for SEC filings, ensuring data is easily accessible and comparable across companies.

Stakeholder Impact

• The amendment ensures that stakeholders have access to fully compliant financial information.
• The discussion of cybersecurity risks highlights the company's awareness of potential threats to its operations and data.

Key Dates

Keywords

XBRL, 10-K/A, Amendment, Cybersecurity, Financial Reporting, Immix Biopharma